GlassScriptPhysician profile
Nina Talukdar
NPI 1881270247
$1,451.13
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $324 · 2023: $559 · 2024: $39.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $426.78 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $249.43 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $124.99 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $109.50 | 2021-2023 | Camzyos |
| Alexion Pharmaceuticals, INC. | $87.03 | 2021-2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $67.68 | 2022-2023 | Lupkynis |
| Boston Scientific Corporation | $64.29 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $55.38 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $50.26 | 2022 | |
| Melinta Therapeutics, LLC | $47.60 | 2021-2023 | Vabomere, Orbactiv, Kimyrsa |
| Lilly USA, LLC | $40.70 | 2023 | Mounjaro, Humulin |
| Amgen INC. | $28.21 | 2023 | Tavneos |
| Aroa Biosurgery Incorporated | $26.66 | 2022 | |
| Mylan Specialty L.P. | $23.32 | 2024 | Yupelri |
| Genentech USA, INC. | $18.94 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.98 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $14.38 | 2023 | Vraylar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Talukdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.